<DOC>
	<DOC>NCT01062048</DOC>
	<brief_summary>The objectives of this survey are: 1) To examine the safety/efficacy profile of Januvia in Korean participants, and 2) To identify factors that might have an influence on the safety and efficacy profile of Januvia in Korean participants. Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.</brief_summary>
	<brief_title>Januvia Re-examination Study (MK-0431-181)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 Diabetes Mellitus Treated With Januvia within local label for the first time Contraindication to Januvia according to the local label Treated with Januvia before contract and out of enrollment period Inclusion criteria for longterm surveillance Treated with Januvia for more than or equal to 24 weeks</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>